Approved for use through 10/31/2002 OMB 0651-0031

Vi Per Hie	Paperwo	rk Reduction Act	of 1995, no	persons are re	equired to respo				tains a valid OMB control number	
P	TA SO	<del></del>		·			Complete i	f Knov	vn	
	Substitute for Form 1449/A/PTO						Application No. 10.		1,458	
pc1 0 5 1	ָטָ מון פּטעו	)				Filing Date		09/10/	2003	
	NF.6	RMATIO	N DIS	CLOSU	RE	First Named Inventor Pace		Pace e	t al.	
TETRASSIATEMENT BY A				Y APPLICANT		Group Art Unit 1616		1616	6	
	INFORMATION DISCLOSURE  TRASSIATEMENT BY APPLICANT  (use as manv sheets as necessarv)					Examiner Name Ern		Ernst	V. Arnold	
Sheet						Attorney Docket Number QRX		QRX-	0300 (15005.105005)	
	-					<del></del>				
	U.S. PATENT DOCUMENTS									
Examiner	Cite	U.S. Pai	tent Docum				Date of Publicat		Pages, Columns, Lines, Where	
Initials	No.1 Kind		Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document		of Cited Document MM-DD-YYYY		Relevant Passages or Relevant Figures Appear		
	1	2007/003	1489	Al	Pace et al.		02/08/2007			

Examiner	Date	
Signature	Considered	

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

							Complete if Known				
		Subst	itute for F	orm 1449/A	/PTO		Application No	o	10/6	61,458	
								Filing Date		09/10/2003	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT						URE	First Named Ir	nventor	Pace	et al.	
						ANT	Group Art Uni	it	1616	5	
(use as many sheets as necessary)							Examiner Nan	ne	Erns	t V. Arnold	
Sheet 2 of 5							Attorney Dock	et Number	QRX	K-0300 (15005.105005)	
				_							
					FO	REIGN PATI	ENT DOCUME	NTS			
Examiner Initials	Cite No.1	Office <sup>3</sup>				Name of	of Patentee or of Cited Document MM-DD-Y		ument	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	2	EP	166	7723		QRx Pharma Pty	y, Ltd.	06/14/20	006		
	3	JР	2007-	505139	A	QRx Pharma Pty	y, Ltd	03/08/20	007		No
	4	wo	1996/	016063	Al	British Technolo	ogy Group Limited	05/30/19	996		
	5	wo	1997/	014438	Al	The University of	of Queensland et al.	04/24/19	997		
	6	wo	2005/	025621	A1	QRx Pharma Pt	y, Ltd.	03/24/20	005		

		I
Examiner	Date	
Signature	Considered	

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Application No. 10/661,458 Substitute for Form 1449/A/PTO 09/10/2003 Filing Date INFORMATION DISCLOSURE First Named Inventor Pace et al. STATEMENT BY APPLICANT Group Art Unit 1616 (use as many sheets as necessary) **Examiner Name** Ernst V. Arnold Attorney Docket Number QRX-0300 (15005.105005) 3 Sheet of 5 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Initials No. publisher, city and/or country where published Title: Office Action Issued Against U.S. Application No. 11/544,187 7 Author: Publ: Date: 03/28/2008 Vol/iss: Pages: 1-13 Title: Office Action Issued Against U.S. Application No. 11/544,187 Author: Publ: Vol/Iss: Pages: 1-18 Date: 06/25/2009 Author: BOLAN et al. Title: Synergy Between Mu Opioid Ligands: Evidence for Functional Interactions Among Mu Opioid Receptor Subtypes Publ: J of Pharmacol, and Exp. Therapeutics Vol/lss: 303 (2) Pages: 557-562 Date: 11/01/2002 Title: Pronounced, Episodic Oxygen Desaturation in the Postoperative Period: Its 10 Author: CATLEY et al. Association with Ventilatory Pattern and Analgesic Regimen Publ: Anesthesiology Vol/Iss: 63 Pages: 20-28 Date: 01/01/1985 Title: The Effects of Residual Pain on Oxygenation and Breathing Pattern During Author: COMBES et al. Morphine Analgesia Publ: Anesth, Analg, Vol/Iss: 90 01/01/2000 Pages: 156-160 Date: Author: CONNOR et al. Title: µ-Opioid Receptor Desensitization: Is Morphine Different? British Journal of Pharmacology Vol/iss: 143 Pages: 685-696 Date: 01/01/2004 Title: Can Coadministration of Oxycodone and Morphine Produce Analgesic Synergy in Author: GRACH et al. 13 Humans? An Experimental Cold Pain Study British Journal of Clinical Pharmacology Vol/lss: 58 (3) Pages: 235-242 Date: 01/01/2004

	<del></del>	***	
Examiner		Date	
Signature		Considered	

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

-			Comp	lete if Known
		Substitute for Form 1449/A/PTO	Application No.	10/661,458
			Filing Date	09/10/2003
	NFO	RMATION DISCLOSURE	First Named Inventor	Pace et al.
S	TAT	TEMENT BY APPLICANT	Group Art Unit	1616
		(use as many sheets as necessary)	Examiner Name	Ernst V. Arnold
Sheet		4 of 5	Attorney Docket Number	QRX-0300 (15005.105005)
				•
		OTHER PRIOR ART - NON F	PATENT LITERATURE DOC	UMENTS
Examiner	Cite		AL LETTERS), title of the article (when	
Initials	No.1		ymposium, catalog, etc.), date, page(s), v city and/or country where published	olume-issue number(s),
	14		rolled-Release Oxycodone and Morphine	in Cancer Related Pain
		Publ:		
		Pain		
		Vol	/lss: 73 Pages: 37-	45 Date: 01/01/1997
	15	Author: KALSO et al. Title: Intrav	renous Morphine and Oxycodone for Pai	n After Abdominal Surgery
		Publ:		
		Acta Anaesthesiologica Scandinavica		
		Vol	/lss: 35 Pages: 642	2-646 Date: 01/01/1991
	16		lesis and Analgesic Activity of Some 14	Beta-Substituted Analogues of
		Publ:	nine	
		J Med Chem		
		T	/Iss: 23 (2) Pages: 1	Date: 02/01/1980
	17	Author: RAEHAL et al. Title: Mu C	pioid Receptor Regulation and Opiate R	esponsiveness
		Publ:		
		The AAPS Journal	Han. 7 (2)	97 F501 D 4 40/40/2005
	L		(Iss: 7 (3) Pages: E5	87-E591 Date: 10/19/2005
	18		odone for Cancer-Related Pain	
		Publ: Arch Intern Med		
			/Iss: 166 Pages: 83	7-843 Date: 04/24/2006
	19		uctive Sleep Apnea Surgery: Risk Manag	
	'	Publ:		
		Otolaryngology - Head and Neck Surgery		
		Vol	/Iss: 117(6) Pages: 648	8-652 Date: 12/01/1997
	20	P	ntrinsic Antinociceptive Effects of Oxyco	odone Appear to be Kappa-Opioid
		Rece	otor Mediated	
		Pain		
		Vol	/Iss: 73 (2) Pages: 15	1-157 Date: 11/01/1997

	<del></del>	т	
Examiner		Date	
Signature		Considered	

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

			Comple	te if Known		
		Substitute for Form 1449/A/PTO	Application No.	10/661,458		
			Filing Date	09/10/2003		
I)	NFO	RMATION DISCLOSURE	First Named Inventor	Pace et al.		
S	TAT	TEMENT BY APPLICANT	Group Art Unit	1616		
		(use as many sheets as necessary)	Examiner Name	Ernst V. Arnold		
Sheet 5 of 5			Attorney Docket Number	QRX-0300 (15005.105005)		
*****	· ·	OTHER PRIOR ART - NON P	ATENT LITERATURE DOCU	MENTS		
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				
	21	Author: SMITH et al.  Title: Neuroexcitatory Effects of Morphine and Hydromorphone: Evidence Implicating the 3-glucuronide Metabolites  Publ: Clin. Exp. Pharmacol. Physiol.				
		Vol/	lss: 27 (7) Pages: 524-	528 Date: 07/01/2000		

Examiner	Date	
Signature	Considered	